Please login to the form below

Not currently logged in
Email:
Password:

Abbott's paediatric HIV drug wins FDA approval

US-based pharmaceutical company Abbott wins FDA approval for its lower-strength protease-inhibitor Kaletra, which will be available in the US from November 2007

US-based pharmaceutical company Abbott has won FDA approval for its lower-strength protease-inhibitor Kaletra (lopinavir/ritonavir), which will be available in the US from November 2007.

The new lower-strength tablets are smaller in size than original Kaletra tablets and contain the same proven active ingredients as Abbott's Kaletra oral solution. The lower-strength Kaletra tablet is approved for children weighing 15 kg or more who are able to swallow the intact tablet.

Scott Brun, divisional vice-president of infectious diseases and renal development at Abbott's global pharmaceutical R&D arm, said: "HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world. Abbott developed a lower-strength tablet formulation of Kaletra to give doctors an innovative treatment option to help curb the impact of HIV infection in children."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics